Join
Live feed
·
PRReleasevia Quantisnow
Definium Therapeutics Inc. logo

Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results

ByQuantisnow·Wall Street's wire, on your screen.
DFTX· Definium Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track DFTX (Definium Therapeutics Inc.) and more on Quantisnow.